用于持续释放剂量形式的用细胞素丰富的聚3-基酸) 纤维
Anna Czerniecka-Kubicka1, Marcin Skotnicki2, Weronika Gonciarz3
1Department of Experimental and Clinical Pharmacology, Medical College of Rzeszow University, The University of Rzeszow, 35-310 Rzeszow, Poland; Centre of Polymer Systems, Tomas Bata University in Zlin, trida Tomase Bati 5678, 760-01 Zlin, Czech Republic.
International journal of biological macromolecules
|June 25, 2023
概括
用细胞素丰富的电聚3-基酸) 纤维提供延迟释放. 这些具有生物相容性和免疫安全性证实的纳米纤维显示出延长细胞因素递送配方的前景.
科学领域:
- 聚合物科学 聚合物科学
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 聚3-基酸盐 (PHB) 是一种具有潜在生物医学应用的可生物降解聚合物.
- 素是一种具有药理活性的类化合物,但其快速释放可能会限制治疗疗效.
- 开发细胞因素的控制释放系统对于优化其治疗潜力至关重要.
研究的目的:
- 通过电制造素丰富的聚3-基酸) 纳米纤维.
- 描述开发的纳米纤维的形态学,热性质和细胞因素释放动力学.
- 为了评估含有细胞素的PHB纳米纤维的生物相容性和免疫安全性.
主要方法:
- 聚3-基酸盐) 的电与细胞素.
- 扫描电子显微镜 (SEM) 用于形态评估.
- 先进的热分析,包括差异扫描热量计 (DSC),以研究热过渡和结晶性.
- 在体外溶解研究以评估细胞素释放动力学.
- 按照监管指南进行生物相容性和免疫安全性评估.
主要成果:
- 成功制造出具有受控形态的素丰富PHB纳米纤维.
- 先进的热分析提供了对玻璃过渡,化/结晶以及无形/晶体部分的见解.
- 与市场上销售的产品相比,从纳米纤维释放的花素表现出延迟的动力学效果.
- 开发的聚合物纳米纤维证明了已确认的免疫安全性和生物相容性.
结论:
- 基于聚3-基酸的聚合物细胞素丰富纤维通过电成功制造.
- 开发的纳米纤维表现出受控的细胞因素释放,提供延长的传递概况.
- 已确认的生物相容性和免疫安全性表明,这些含有细胞素的PHB纳米纤维是先进药物输送配方的有希望的候选者.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
230
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
230
Drugs for Treatment of Diarrhea-Predominant IBS
218
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
218


